MyFinsight
Home
Blog
About
Contact
Download
Download image
Net loss
attributable to common...
-$12,351K
(8.10%↑ Y/Y)
Interest income
$506K
(-46.23%↓ Y/Y)
Net loss
-$12,345K
(8.11%↑ Y/Y)
Preferred stock dividend
payable on series a...
$6K
(0.00%↑ Y/Y)
Total other income
(expense), net
$505K
(-46.73%↓ Y/Y)
Other income
(expense), net
-$1K
(-114.29%↓ Y/Y)
Loss from operations
-$12,850K
(10.65%↑ Y/Y)
Royalty revenues
$41K
(-62.39%↓ Y/Y)
Total operating
expenses
$12,891K
(-11.04%↓ Y/Y)
Research and development
$6,765K
(-35.43%↓ Y/Y)
Selling, general and
administrative
$6,126K
(52.62%↑ Y/Y)
Back
Back
Income Statement
source: myfinsight.com
Cardiff Oncology, Inc. (CRDF)
Cardiff Oncology, Inc. (CRDF)